Clinical Trial

Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The objective of this study is to assess the efficacy and safety of vadadustat for treating hospitalized patients with nonintubated Acute Respiratory Distress Syndrome (ARDS) secondary to pathogen-associated lung injury.
Protocol Amendment History 3 changes
notable Sponsor changed: Bentley J. Bobrow -> Paul Potnuru 2026-08-11
notable Primary completion pushed: 2026-07-01 -> 2031-05-31 2026-08-11
minor Completion pushed: 2026-07-01 -> 2031-05-31 2026-08-11
Trial Details
NCT Number NCT07086755
Lead Sponsor Paul Potnuru
Collaborators: Akebia Therapeutics
Conditions Nonintubated Acute Respiratory Distress Syndrome (ARDS), Pathogen-associated Lung Injury
Enrollment 1,100 participants
Start Date 2025-10-23
Primary Completion 2031-05-31 (estimated)
Study Completion 2031-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10